Ascendis Pharma A/S (NASDAQ:ASND) had its target price hoisted by JPMorgan Chase & Co. to $75.00 in a research note published on Wednesday morning. The firm currently has an overweight rating on the biotechnology company’s stock.

Several other equities research analysts have also recently weighed in on ASND. Credit Suisse Group increased their target price on Ascendis Pharma A/S from $50.00 to $78.00 and gave the company an outperform rating in a report on Tuesday. Zacks Investment Research upgraded Ascendis Pharma A/S from a sell rating to a hold rating in a report on Thursday, March 1st. Wedbush restated an outperform rating and set a $62.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, February 6th. BidaskClub upgraded Ascendis Pharma A/S from a hold rating to a buy rating in a report on Wednesday, December 27th. Finally, HC Wainwright restated a buy rating on shares of Ascendis Pharma A/S in a report on Friday, January 19th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $59.83.

How to Become a New Pot Stock Millionaire

ASND stock opened at $66.04 on Wednesday. Ascendis Pharma A/S has a fifty-two week low of $21.95 and a fifty-two week high of $69.00.

A number of hedge funds have recently modified their holdings of the stock. VHCP Management II LLC raised its position in Ascendis Pharma A/S by 31.7% during the 3rd quarter. VHCP Management II LLC now owns 1,299,052 shares of the biotechnology company’s stock valued at $47,091,000 after purchasing an additional 312,560 shares during the last quarter. Millennium Management LLC raised its position in Ascendis Pharma A/S by 3.6% during the 4th quarter. Millennium Management LLC now owns 530,791 shares of the biotechnology company’s stock valued at $21,263,000 after purchasing an additional 18,377 shares during the last quarter. BlackRock Inc. bought a new position in Ascendis Pharma A/S during the 4th quarter valued at approximately $17,279,000. JPMorgan Chase & Co. bought a new position in Ascendis Pharma A/S during the 3rd quarter valued at approximately $7,163,000. Finally, Allianz Asset Management GmbH raised its position in Ascendis Pharma A/S by 48.1% during the 4th quarter. Allianz Asset Management GmbH now owns 178,370 shares of the biotechnology company’s stock valued at $7,145,000 after purchasing an additional 57,920 shares during the last quarter. Institutional investors own 73.48% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Ascendis Pharma A/S (ASND) Given New $75.00 Price Target at JPMorgan Chase & Co.” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/ascendis-pharma-a-s-asnd-given-new-75-00-price-target-at-jpmorgan-chase-co/1956431.html.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.